Supplementary Table I: Postmarketing Safety of Bimekizumab for Hidradenitis Suppurativa: An Early Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System

Published: 26 January 2026| Version 1 | DOI: 10.17632/wxnmgt7khb.1
Contributors:
,
,
,

Description

Clinical Characteristics of Adverse Event (AE) Reports Associated with Bimekizumab in the treatment of Hidradenitis Suppurativa (n=239 AE reports total). AE, Adverse Event.

Files

Institutions

  • University of Pennsylvania Department of Dermatology
    PA, Philadelphia

Categories

Adverse Event, Demographics

Licence